Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

First Observation of P-odd γ Asymmetry in Polarized Neutron Capture on Hydrogen.

Blyth D, Fry J, Fomin N, Alarcon R, Alonzi L, Askanazi E, Baeßler S, Balascuta S, Barrón-Palos L, Barzilov A, Bowman JD, Birge N, Calarco JR, Chupp TE, Cianciolo V, Coppola CE, Crawford CB, Craycraft K, Evans D, Fieseler C, Frlež E, Garishvili I, Gericke MTW, Gillis RC, Grammer KB, Greene GL, Hall J, Hamblen J, Hayes C, Iverson EB, Kabir ML, Kucuker S, Lauss B, Mahurin R, McCrea M, Maldonado-Velázquez M, Masuda Y, Mei J, Milburn R, Mueller PE, Musgrave M, Nann H, Novikov I, Parsons D, Penttilä SI, Počanić D, Ramirez-Morales A, Root M, Salas-Bacci A, Santra S, Schröder S, Scott E, Seo PN, Sharapov EI, Simmons F, Snow WM, Sprow A, Stewart J, Tang E, Tang Z, Tong X, Turkoglu DJ, Whitehead R, Wilburn WS; NPDGamma Collaboration.

Phys Rev Lett. 2018 Dec 14;121(24):242002. doi: 10.1103/PhysRevLett.121.242002.

PMID:
30608729
2.

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.

Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buchwalter G, Houtman R, Toy W, Fowler CE, Han R, Lainé M, Carlson KE, Martin TA, Nowak J, Nwachukwu JC, Hosfield DJ, Chandarlapaty S, Tajkhorshid E, Nettles KW, Griffin PR, Shen Y, Katzenellenbogen JA, Brown M, Greene GL.

Elife. 2018 Nov 29;7. pii: e37161. doi: 10.7554/eLife.37161.

3.

Publisher Correction: Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.

Katzenellenbogen JA, Mayne CG, Katzenellenbogen BS, Greene GL, Chandarlapaty S.

Nat Rev Cancer. 2018 Oct;18(10):662. doi: 10.1038/s41568-018-0053-0.

PMID:
30185950
4.

Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity.

Fanning SW, Hodges-Gallagher L, Myles DC, Sun R, Fowler CE, Plant IN, Green BD, Harmon CL, Greene GL, Kushner PJ.

Nat Commun. 2018 Jun 18;9(1):2368. doi: 10.1038/s41467-018-04413-3.

5.

Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer.

Maximov PY, Abderrahman B, Fanning SW, Sengupta S, Fan P, Curpan RF, Rincon DMQ, Greenland JA, Rajan SS, Greene GL, Jordan VC.

Mol Pharmacol. 2018 Aug;94(2):812-822. doi: 10.1124/mol.117.111385. Epub 2018 May 8.

6.

A "cross-stitched" peptide with improved helicity and proteolytic stability.

Speltz TE, Mayne CG, Fanning SW, Siddiqui Z, Tajkhorshid E, Greene GL, Moore TW.

Org Biomol Chem. 2018 May 23;16(20):3702-3706. doi: 10.1039/c8ob00790j.

PMID:
29725689
7.

Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.

Katzenellenbogen JA, Mayne CG, Katzenellenbogen BS, Greene GL, Chandarlapaty S.

Nat Rev Cancer. 2018 Jun;18(6):377-388. doi: 10.1038/s41568-018-0001-z. Review. Erratum in: Nat Rev Cancer. 2018 Oct;18(10):662.

8.

Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.

West DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, Hosfield DJ, Lastra RR, Sinnwell JP, Thompson KJ, Bowie KR, Harkless RV, Skor MN, Pierce CF, Styke SC, Kim CR, de Wet L, Greene GL, Boughey JC, Goetz MP, Kalari KR, Wang L, Fleming GF, Györffy B, Conzen SD.

Clin Cancer Res. 2018 Jul 15;24(14):3433-3446. doi: 10.1158/1078-0432.CCR-17-2793. Epub 2018 Apr 10.

PMID:
29636357
9.

Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling.

Singhal H, Greene ME, Zarnke AL, Laine M, Al Abosy R, Chang YF, Dembo AG, Schoenfelt K, Vadhi R, Qiu X, Rao P, Santhamma B, Nair HB, Nickisch KJ, Long HW, Becker L, Brown M, Greene GL.

Oncotarget. 2017 Sep 28;9(4):4282-4300. doi: 10.18632/oncotarget.21378. eCollection 2018 Jan 12.

10.

Metabolism of megestrol acetate in vitro and the role of oxidative metabolites.

House L, Seminerio MJ, Mirkov S, Ramirez J, Skor M, Sachleben JR, Isikbay M, Singhal H, Greene GL, Vander Griend D, Conzen SD, Ratain MJ.

Xenobiotica. 2018 Oct;48(10):973-983. doi: 10.1080/00498254.2017.1386335. Epub 2017 Nov 10.

PMID:
29050522
11.

Interferon-Stimulated Genes Are Transcriptionally Repressed by PR in Breast Cancer.

Walter KR, Goodman ML, Singhal H, Hall JA, Li T, Holloran SM, Trinca GM, Gibson KA, Jin VX, Greene GL, Hagan CR.

Mol Cancer Res. 2017 Oct;15(10):1331-1340. doi: 10.1158/1541-7786.MCR-17-0180. Epub 2017 Jul 6.

12.

Capture of associated targets on chromatin links long-distance chromatin looping to transcriptional coordination.

Bourgo RJ, Singhal H, Greene GL.

Nat Commun. 2016 Sep 16;7:12893. doi: 10.1038/ncomms12893.

13.

Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.

Singhal H, Greene ME, Tarulli G, Zarnke AL, Bourgo RJ, Laine M, Chang YF, Ma S, Dembo AG, Raj GV, Hickey TE, Tilley WD, Greene GL.

Sci Adv. 2016 Jun 24;2(6):e1501924. doi: 10.1126/sciadv.1501924. eCollection 2016 Jun.

14.

The Neutron Enigma.

Greene GL, Geltenbort P.

Sci Am. 2016 Apr;314(4):36-41. doi: 10.1038/scientificamerican0416-36. No abstract available.

PMID:
27082189
15.

Stapled Peptides with γ-Methylated Hydrocarbon Chains for the Estrogen Receptor/Coactivator Interaction.

Speltz TE, Fanning SW, Mayne CG, Fowler C, Tajkhorshid E, Greene GL, Moore TW.

Angew Chem Int Ed Engl. 2016 Mar 18;55(13):4252-5. doi: 10.1002/anie.201510557. Epub 2016 Mar 1.

16.

Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.

Fanning SW, Mayne CG, Dharmarajan V, Carlson KE, Martin TA, Novick SJ, Toy W, Green B, Panchamukhi S, Katzenellenbogen BS, Tajkhorshid E, Griffin PR, Shen Y, Chandarlapaty S, Katzenellenbogen JA, Greene GL.

Elife. 2016 Feb 2;5. pii: e12792. doi: 10.7554/eLife.12792.

17.

14q32-encoded microRNAs mediate an oligometastatic phenotype.

Uppal A, Wightman SC, Mallon S, Oshima G, Pitroda SP, Zhang Q, Huang X, Darga TE, Huang L, Andrade J, Liu H, Ferguson MK, Greene GL, Posner MC, Hellman S, Khodarev NN, Weichselbaum RR.

Oncotarget. 2015 Feb 28;6(6):3540-52.

18.

The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor α modulation, uncoupling nuclear and membrane activation.

Abot A, Fontaine C, Buscato M, Solinhac R, Flouriot G, Fabre A, Drougard A, Rajan S, Laine M, Milon A, Muller I, Henrion D, Adlanmerini M, Valéra MC, Gompel A, Gerard C, Péqueux C, Mestdagt M, Raymond-Letron I, Knauf C, Ferriere F, Valet P, Gourdy P, Katzenellenbogen BS, Katzenellenbogen JA, Lenfant F, Greene GL, Foidart JM, Arnal JF.

EMBO Mol Med. 2014 Oct;6(10):1328-46. doi: 10.15252/emmm.201404112.

19.

Improved determination of the neutron lifetime.

Yue AT, Dewey MS, Gilliam DM, Greene GL, Laptev AB, Nico JS, Snow WM, Wietfeldt FE.

Phys Rev Lett. 2013 Nov 27;111(22):222501. Epub 2013 Nov 27.

PMID:
24329445
20.

In memoriam: Elwood Jensen (1920-2012).

Greene GL.

Endocr Rev. 2013 Dec;34(6):761-3. doi: 10.1210/er.2013-7031. No abstract available.

PMID:
24319151
21.

Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivo.

O'Leary KA, Jallow F, Rugowski DE, Sullivan R, Sinkevicius KW, Greene GL, Schuler LA.

Endocrinology. 2013 Dec;154(12):4483-92. doi: 10.1210/en.2013-1533. Epub 2013 Sep 24.

22.

In memoriam: Elwood Jensen (1920-2012).

Greene GL.

Endocrinology. 2013 Oct;154(10):3489-91. doi: 10.1210/en.2013-1009. No abstract available.

PMID:
24058153
23.

Mapping ERβ genomic binding sites reveals unique genomic features and identifies EBF1 as an ERβ interactor.

Le TP, Sun M, Luo X, Kraus WL, Greene GL.

PLoS One. 2013 Aug 8;8(8):e71355. doi: 10.1371/journal.pone.0071355. eCollection 2013.

24.

Cross-talk between the ligand- and DNA-binding domains of estrogen receptor.

Huang W, Greene GL, Ravikumar KM, Yang S.

Proteins. 2013 Nov;81(11):1900-9. doi: 10.1002/prot.24331. Epub 2013 Aug 19.

PMID:
23737157
25.

Examining the pathogenesis of breast cancer using a novel agent-based model of mammary ductal epithelium dynamics.

Chapa J, Bourgo RJ, Greene GL, Kulkarni S, An G.

PLoS One. 2013 May 21;8(5):e64091. doi: 10.1371/journal.pone.0064091. Print 2013.

26.

Overcoming mutation-based resistance to antiandrogens with rational drug design.

Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL.

Elife. 2013 Apr 9;2:e00499. doi: 10.7554/eLife.00499.

27.

MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11.

Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T, Lu J, Park SY, Dolan ME, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H.

Nat Commun. 2013;4:1393. doi: 10.1038/ncomms2393.

28.

MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion.

Bockhorn J, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H.

Breast Cancer Res Treat. 2013 Jan;137(2):373-82. doi: 10.1007/s10549-012-2346-4. Epub 2012 Dec 7.

29.

The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.

Romero IL, Lee W, Mitra AK, Gordon IO, Zhao Y, Leonhardt P, Penicka CV, Mui KL, Krausz TN, Greene GL, Lengyel E.

Gynecol Oncol. 2012 Jan;124(1):134-41. doi: 10.1016/j.ygyno.2011.08.026. Epub 2011 Oct 11.

30.

Removal of lactate dehydrogenase-elevating virus from human-in-mouse breast tumor xenografts by cell-sorting.

Liu H, Bockhorn J, Dalton R, Chang YF, Qian D, Zitzow LA, Clarke MF, Greene GL.

J Virol Methods. 2011 May;173(2):266-70. doi: 10.1016/j.jviromet.2011.02.015. Epub 2011 Feb 24.

31.

RAC3 is a pro-migratory co-activator of ERα.

Walker MP, Zhang M, Le TP, Wu P, Lainé M, Greene GL.

Oncogene. 2011 Apr 28;30(17):1984-94. doi: 10.1038/onc.2010.583. Epub 2011 Jan 10.

32.

Characterization of the ovarian and reproductive abnormalities in prepubertal and adult estrogen non-responsive estrogen receptor alpha knock-in (ENERKI) mice.

Sinkevicius KW, Woloszyn K, Laine M, Jackson KS, Greene GL, Woodruff TK, Burdette JE.

Steroids. 2009 Nov;74(12):913-9. doi: 10.1016/j.steroids.2009.06.012. Epub 2009 Jul 23.

33.

Estrogen-dependent and -independent estrogen receptor-alpha signaling separately regulate male fertility.

Sinkevicius KW, Laine M, Lotan TL, Woloszyn K, Richburg JH, Greene GL.

Endocrinology. 2009 Jun;150(6):2898-905. doi: 10.1210/en.2008-1016. Epub 2009 Mar 5.

34.

Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.

Haiman CA, Garcia RR, Hsu C, Xia L, Ha H, Sheng X, Le Marchand L, Kolonel LN, Henderson BE, Stallcup MR, Greene GL, Press MF.

BMC Cancer. 2009 Jan 30;9:43. doi: 10.1186/1471-2407-9-43.

35.

Green tea catechins inhibit angiogenesis through suppression of STAT3 activation.

Leong H, Mathur PS, Greene GL.

Breast Cancer Res Treat. 2009 Oct;117(3):505-15. doi: 10.1007/s10549-008-0196-x. Epub 2008 Sep 28.

36.

Modulation of alphaCaMKII signaling by rapid ERalpha action.

O'Neill EE, Blewett AR, Loria PM, Greene GL.

Brain Res. 2008 Jul 30;1222:1-17. doi: 10.1016/j.brainres.2008.05.036. Epub 2008 May 23.

37.

NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses.

Nettles KW, Bruning JB, Gil G, Nowak J, Sharma SK, Hahm JB, Kulp K, Hochberg RB, Zhou H, Katzenellenbogen JA, Katzenellenbogen BS, Kim Y, Joachmiak A, Greene GL.

Nat Chem Biol. 2008 Apr;4(4):241-7. doi: 10.1038/nchembio.76. Epub 2008 Mar 16. Erratum in: Nat Chem Biol. 2008 Jun;4(6):379.

38.

An estrogen receptor-alpha knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo.

Sinkevicius KW, Burdette JE, Woloszyn K, Hewitt SC, Hamilton K, Sugg SL, Temple KA, Wondisford FE, Korach KS, Woodruff TK, Greene GL.

Endocrinology. 2008 Jun;149(6):2970-9. doi: 10.1210/en.2007-1526. Epub 2008 Mar 13.

39.
40.

CBP Is a dosage-dependent regulator of nuclear factor-kappaB suppression by the estrogen receptor.

Nettles KW, Gil G, Nowak J, Métivier R, Sharma VB, Greene GL.

Mol Endocrinol. 2008 Feb;22(2):263-72. Epub 2007 Oct 11.

41.

Elemental isomerism: a boron-nitrogen surrogate for a carbon-carbon double bond increases the chemical diversity of estrogen receptor ligands.

Zhou HB, Nettles KW, Bruning JB, Kim Y, Joachimiak A, Sharma S, Carlson KE, Stossi F, Katzenellenbogen BS, Greene GL, Katzenellenbogen JA.

Chem Biol. 2007 Jun;14(6):659-69.

42.

Inhibition of mammary tumorigenesis in the C3(1)/SV40 mouse model by green tea.

Leong H, Mathur PS, Greene GL.

Breast Cancer Res Treat. 2008 Feb;107(3):359-69. Epub 2007 May 5.

PMID:
17484049
43.

Structural plasticity in the oestrogen receptor ligand-binding domain.

Nettles KW, Bruning JB, Gil G, O'Neill EE, Nowak J, Guo Y, Kim Y, DeSombre ER, Dilis R, Hanson RN, Joachimiak A, Greene GL.

EMBO Rep. 2007 Jun;8(6):563-8. Epub 2007 Apr 27. Erratum in: EMBO Rep. 2007 Jun;8(6):610. Guo, Yuee [added]; Hughs, Alun [removed].

44.

Structure-guided optimization of estrogen receptor binding affinity and antagonist potency of pyrazolopyrimidines with basic side chains.

Zhou HB, Sheng S, Compton DR, Kim Y, Joachimiak A, Sharma S, Carlson KE, Katzenellenbogen BS, Nettles KW, Greene GL, Katzenellenbogen JA.

J Med Chem. 2007 Jan 25;50(2):399-403.

PMID:
17228884
45.

Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity.

Hsieh RW, Rajan SS, Sharma SK, Guo Y, DeSombre ER, Mrksich M, Greene GL.

J Biol Chem. 2006 Jun 30;281(26):17909-19. Epub 2006 Apr 28.

46.

Conformation-specific affinity purification of proteins using engineered binding proteins: application to the estrogen receptor.

Huang J, Koide A, Nettle KW, Greene GL, Koide S.

Protein Expr Purif. 2006 Jun;47(2):348-54. Epub 2005 Nov 14.

PMID:
16325424
47.

Label-free detection of protein-protein interactions on biochips.

Yeo WS, Min DH, Hsieh RW, Greene GL, Mrksich M.

Angew Chem Int Ed Engl. 2005 Aug 26;44(34):5480-3. No abstract available.

PMID:
16052641
48.

Recruitment of histone deacetylase 4 to the N-terminal region of estrogen receptor alpha.

Leong H, Sloan JR, Nash PD, Greene GL.

Mol Endocrinol. 2005 Dec;19(12):2930-42. Epub 2005 Jul 28.

PMID:
16051668
49.

Structural basis for an unexpected mode of SERM-mediated ER antagonism.

Wu YL, Yang X, Ren Z, McDonnell DP, Norris JD, Willson TM, Greene GL.

Mol Cell. 2005 May 13;18(4):413-24.

50.

Ligand control of coregulator recruitment to nuclear receptors.

Nettles KW, Greene GL.

Annu Rev Physiol. 2005;67:309-33. Review.

PMID:
15709961

Supplemental Content

Loading ...
Support Center